Medical M&A deals abroad to continue

Deloitte report downplays the impact of capital outflow controls on healthcare

Despite recent controls on capital outflows, Chinese healthcare and life science companies will continue to find ample opportunities for mergers and acquisitions or M&A abroad, according to a report by Deloitte Touche Tohmatsu, one of the "Big Four" global accounting firms.

The recent slowdown in health-related M&A notwithstanding, Chinese overseas investments will accelerate, especially in medical equipment and related services, given the inadequate research and development capabilities at home, expectations of the renminbi's depreciation and overvalued domestic M&A targets, said the DTT report.